Experimental treatment pushed by ALS patients gets day before FDA but agency unconvinced it works

WASHINGTON — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by patients with the fatal neurodegenerative disease. Those advocates still face one giant hurdle: FDA regulators say the treatment hasn’t been shown…Read More